Apax-advised funds sign definitive agreement to obtain interest in Ideal Protein Funds advised by Apax Partners LLP , a worldwide private equity firm, today announced they have entered into a definitive agreement to acquire an interest in Ideal Protein, a proprietary fat wellness and loss solutions company. Terms of the transaction were not disclosed prednisolone20mg.net/rheumatoid-arthritis.html . Ideal Protein is rolling out a comprehensive protocol that’s designed to help individuals effectively achieve and maintain their weight-loss goals.
Beneath the conditions of the contract, Apogenix shall receive upfront and milestone payments, as well as royalty payments at tiered, double-digit royalty prices following commercial launch of APG101 in China. APG101 is usually a CD95 ligand inhibitor which restores the immune response against tumors and inhibits invasive tumor cell growth. The drug candidate is being developed for the treatment of solid tumors and malignant hematological diseases. In a controlled stage II proof-of-idea trial in individuals with recurrent glioblastoma, treatment with APG101 in conjunction with radiotherapy has demonstrated clinical superiority in every study endpoints compared to treatment with radiotherapy only.